Vilon Preclinical

What It Is

Vilon is the simplest of all Khavinson short-peptide bioregulators — a dipeptide consisting of just two amino acids, lysine and glutamic acid (Lys-Glu, KE). It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s as a synthetic mimetic of the putative active principle of Thymalin, the calf-thymus polypeptide-complex extract that forms the basis of the Khavinson thymic bioregulator line.

Within the Khavinson framework, Vilon represents a reductionist test case: the claim is that a dipeptide — two amino acids — carries enough "tissue memory" to modulate gene expression in thymic and peripheral immune cells and reproduce (in outline) the biological effects of the larger Thymalin extract. This is the most aggressive version of the Khavinson short-peptide thesis: activity reduced to the minimum possible peptide structure.

Despite its extreme simplicity, Vilon has published biological activity in the Khavinson program — modulating gene expression in immune-cell cultures, supporting T-cell subset balance in aged rodent models, and in the most-cited cohort study (Khavinson & Morozov, Neuro Endocrinol Lett 2003; PMID 14523363) associating with reduced all-cause mortality in elderly St. Petersburg residents over a multi-year follow-up when combined with Epithalon.

Vilon is not FDA- or EMA-approved. In Russia it is registered as a dietary supplement / bioregulator through the Peptide Bioregulation Center and distributed through Khavinson-affiliated commercial channels. Outside Russia it is available from research-chemical vendors for laboratory research purposes. Its very short sequence makes it one of the more orally bioavailable peptide bioregulators and one of the cheapest to manufacture.

Mechanism of Action

• Thymic gene expression modulation — Vilon is proposed to bind specific DNA promoter regions in thymic epithelial cells, modulating expression of genes involved in T-cell education and selection. Biophysical studies of KE-DNA binding have been published from the Khavinson group.
• Peripheral T-cell subset normalization — Russian work describes KE-peptide-induced normalization of CD4/CD8 T-cell ratios and improvement of naïve-to-memory T-cell distributions in aged animal models.
• NK-cell activity support — Enhanced natural killer cell cytotoxicity in aged immune systems reported in Khavinson preclinical publications.
• Anti-senescence signaling — Research claims reduction in cellular senescence markers (SA-β-gal, p16^INK4a) in immune cells treated with Vilon, potentially reversing immunosenescence.
• Telomere-adjacent biology — Some Khavinson reports describe KE-peptide effects on telomerase-related gene expression, with a weaker effect than Epithalon (AEDG) specifically on telomere biology.
• Cytokine balance — Restoration of IL-2, IFN-γ, and TNF-α balance in aged or immunosuppressed hosts, per published Russian work.
• Oral / sublingual bioavailability — As a dipeptide, Vilon has minimal peptidase-cleavage surface area and relatively good oral / sublingual stability — the theoretical basis for Khavinson's oral-first dosing protocols.
• Post-dose persistence — Gene-expression effects claimed to persist weeks after peptide clearance, consistent with a transcriptional rather than receptor-pharmacology mechanism.
• Lysine / glutamate contextual chemistry — The KE dipeptide contains one positively-charged (lysine) and one negatively-charged (glutamate) residue — a minimal motif capable of ionic DNA-groove interaction. The Khavinson biophysical work characterized DNA-binding affinity and sequence preference.
• Thymic epithelial cell differentiation — KE peptide is proposed to affect thymic epithelial cell maturation gene programs, with downstream effects on thymocyte selection and peripheral T-cell diversity.
• NK-cell cytotoxicity support — Restoration of NK-cell function in aged and immunosuppressed models is claimed within the Khavinson framework. NK activity declines with age and is one of the more tractable measurable immune functions.
• Senescence-associated gene modulation — Reduced SA-β-galactosidase and p16^INK4a expression in KE-peptide-treated cells is reported. If replicable, would suggest senolytic-adjacent biology, though this is not the primary Khavinson framing.
• Longevity cohort framing — Within Khavinson's geroprotection framework, Vilon sits alongside Epithalon (pineal / telomerase) as part of the multi-compound "bioregulator" strategy for slowing age-related decline across multiple tissue systems in cyclical dosing protocols.

What the Research Shows

• Khavinson & Morozov 2003 elderly cohort (PMID 14523363) — The most-cited human evidence. Long-term follow-up of 266 elderly St. Petersburg residents randomized to Vilon + Epithalon versus control over multiple years. Combined peptide arm showed reduced all-cause mortality vs controls. The headline "longevity peptide" cohort in the Khavinson corpus.
• Anisimov & Khavinson 2010 review (PMID 19609712) — Biogerontology review summarizing peptide bioregulator evidence in aging, including Vilon's place in the framework.
• Khavinson foundational review (Neuro Endocrinol Lett 2002) — Short-peptide bioregulator theoretical framework.
• Cell-culture gene expression modulation — Bulletin of Experimental Biology and Medicine papers documenting KE-peptide effects on lymphocyte gene expression in vitro.
• Immune subset normalization in aged animals — Rodent studies of CD4/CD8 ratio and NK activity restoration.
• Longevity-protocol context — Vilon + Epithalon is the canonical Khavinson "longevity" combination referenced in multiple Khavinson-group cohort reports.
• Ryzhak, Khavinson, and colleagues — Subsequent Russian group work extending the Khavinson framework to bioregulators of specific systems.
• Independent Western replication — Limited. The 2003 cohort study has not been repeated by independent Western groups with modern methodology.

The 2003 Khavinson & Morozov paper is the anchor point for every downstream "Khavinson peptides extend life" claim. It is not a Western-standard randomized controlled trial — it is a long-term cohort observation in a group of 266 elderly St. Petersburg residents, with treatment assignment and follow-up methodology that predate modern RCT discipline. Its findings (reduced all-cause mortality in the peptide-treated arms compared to controls, with Vilon + Epithalon showing the largest effect) have been cited extensively in the Russian gerontology literature and have shaped global community perception of Khavinson peptides. They have not been replicated in an independently-funded Western RCT at any time in the ~23 years since publication. This absence is significant: short peptides are cheap to synthesize, inexpensive to test, and relatively safe — the barrier to independent replication is primarily one of research-community interest and funding priority, not technical feasibility. The appropriate interpretation is that the 2003 result is a meaningful preliminary signal in a specific cohort under a specific research framework, not a confirmed therapeutic effect generalizable to arbitrary populations.

Human Data

• Khavinson & Morozov 2003 (PMID 14523363) — 266 elderly St. Petersburg subjects; long-term follow-up. Vilon + Epithalon arm reduced all-cause mortality vs control in this cohort. The most-cited human Vilon evidence.
• Elderly immune parameter cohort reports — Small Russian clinical series describing improved lymphocyte subsets, reduced infection rates, and better recovery from immunosuppressive therapies in elderly patients receiving cyclical Vilon courses.
• No Phase 2/3 RCT at Western standards — Vilon has never been the subject of a registrational RCT outside the Khavinson research framework.
• Safety signal — No serious adverse-event signal in Russian published experience; the dipeptide is composed of two common dietary amino acids.
• Cohort limitations — The 2003 cohort study used a combination peptide arm (Vilon + Epithalon), making it impossible to attribute the mortality signal to Vilon alone; blinding, randomization quality, and endpoint adjudication do not match modern RCT standards.
• Gerontological context — Vilon sits within the broader Khavinson-group cohort work over 30+ years describing cyclical short-peptide protocols in elderly Russian cohorts. Pattern-of-evidence across the corpus is suggestive rather than confirmatory at Western regulatory standards.
• No head-to-head vs Thymosin α1 — Despite overlapping immune-restoration claim space, Vilon has never been tested head-to-head against thymosin α1, the one thymic-family peptide with substantive approved-indication evidence. This gap is one of the more conspicuous missing comparisons in the category.
• Kuznik, Linkova, and Ryzhak extension work — Subsequent Khavinson-group collaborators have extended the framework to related short peptides across immune, cardiovascular, and CNS targets. The body of Russian-language and English-translated work is substantial; the confirmatory Western replication is not.

Dosing from the Literature

Reconstitution & Storage

• Identity / purity verification — Third-party HPLC + mass spec is the minimum bar for research-chemical supply.
• Oral / sublingual stability — As a dipeptide, Vilon has greater oral stability than most peptides; sublingual absorption is the typical Khavinson-framework oral route.
• Storage — Stable refrigerated; reconstituted solution should be used within 28 days.

→ Use the Kalios Peptide Calculator for research-context dosing math

Side Effects & Risks

• Extremely well-tolerated — Simplest possible bioactive peptide structure. Excellent Russian clinical safety record.
• No major risks reported — Two common dietary amino acids.
• Theoretical immune interaction — As an immunomodulator, caution in patients with active autoimmune disease or on immunosuppressants.
• Limited Western safety data — No FDA-standard safety studies.
• Pregnancy / lactation — Not studied; avoid.
• Purity / source quality — Research-chemical supply quality varies.
• WADA status — Not specifically named on the WADA Prohibited List. Athletes should consult their federation given S2 umbrella interpretations.
• Active transplant immunosuppression — Theoretical antagonism with cyclosporine, tacrolimus, biologic therapy. Not appropriate for self-administration during transplant management.
• Active chemotherapy / malignancy — Hematopoietic / immune modulation during active cancer treatment requires oncology supervision; not self-administered.
• Injection-site reactions (SubQ) — Mild local erythema, tenderness.
• Mild GI effects — Occasional mild nausea with oral dosing, transient.
• Paradoxical responses — In the Khavinson framework, short-peptide bioregulators are claimed to normalize rather than uniformly stimulate. Distinguishing "normalized" from "non-responding" is difficult without clear pharmacodynamic markers.
• Long-term safety profile — Khavinson cohort follow-up extends over decades in some Russian cohorts without identified major long-term toxicity. However, this observation is within a single research-group framework and carries corresponding methodological limitations.

Bloodwork & Monitoring

• CBC with differential — Baseline lymphocyte / neutrophil / NK subset.
• CMP — Standard baseline liver / kidney function.
• hsCRP / inflammatory markers — Track claimed anti-inflammaging signal.
• Immune subset panel (selective) — T-cell subsets, NK activity if available.
• Vitamin D, zinc — Foundational immune-axis supports.
• Autoimmune markers (if family history) — ANA, RF baseline.
• Lymphocyte subsets (CD4, CD8, CD4/CD8 ratio, NK count) — Flow cytometry panel; useful for quantifying immune-response claim if instrumented.
• Immunoglobulins (IgG, IgA, IgM) — B-cell function baseline.
• Ferritin — Iron status; relevant to broader hematopoietic context.
• TSH, free T4 — Thyroid function (interacts with thymic biology).

Practical Perspective on Khavinson Longevity Framework

The Vilon + Epithalon protocol is the clearest single expression of the Khavinson "longevity peptide" hypothesis — use short cyclical courses of two synthetic peptides (immune-targeted Vilon plus pineal-targeted Epithalon) and potentially extend life span in elderly cohorts. The 2003 mortality signal from Khavinson & Morozov is the strongest specific human evidence in the Khavinson corpus for life-extension.

It is also, 23 years later, still the primary evidence. No independently-funded Western RCT has replicated the 2003 finding with modern methodology. This absence is meaningful: if a cheap, well-tolerated, orally-bioavailable peptide combination genuinely reduced all-cause mortality in elderly populations, one would expect substantial replication effort. The fact that replication has not happened — despite the low cost and relative accessibility of the compounds — suggests the research community's appraisal of the 2003 signal strength is more cautious than the popular "longevity peptide" framing suggests.

Three interpretations are compatible with the existing evidence: (1) the Vilon + Epithalon mortality signal is real and generalizes, representing a genuine but under-investigated geroprotector combination; (2) the signal is real within the specific 2003 cohort context (older Russian residents with particular baseline health and nutritional patterns) but does not generalize to contemporary populations with different baseline conditions; (3) the signal reflects methodological artifacts that would not survive modern study-design standards. None of these can be distinguished from the existing evidence.

Practical implication for research-framework use: if you are drawn to the Khavinson longevity hypothesis, run Vilon + Epithalon cycles understanding that the evidence is preliminary, that lifestyle foundations (sleep, nutrition, exercise, stress management, social connection) have dramatically better evidence for longevity outcomes, and that the peptides are not substitutes for those foundations.

Concretely: document baseline CBC with differential, lymphocyte subsets if available, hsCRP, vitamin D, zinc, ferritin, fasting metabolic parameters. If any are abnormal, optimize them before layering on Vilon. Run a defined 10–20 day course, then reassess the same parameters 4 weeks post-course. Repeat two to three times yearly if the framework is producing defensible objective changes or subjective benefit. Abandon if no measurable or meaningful effect after two or three cycles — continuing a non-responsive intervention wastes time, attention, and resources that could be redirected to better-evidenced interventions.

The dipeptide's extreme simplicity deserves one additional note: Lys-Glu is cheap to synthesize, easy to dilute or adulterate, and extremely cheap to counterfeit. Research-chemical supply at commodity-vendor scale is therefore at particular quality risk. Independent third-party COA is not optional — it is the only way to distinguish actual KE from a capsule of filler or a mislabeled unrelated peptide. If a vendor refuses to provide independent-lab COA, assume the worst.

A final epistemic note: the Khavinson bioregulator framework sits at a peculiar place in modern biomedical science. The corpus is substantial, internally coherent, and includes genuine biochemistry and cohort observations. It also operates largely outside the Western evidence-based medicine framework that defines therapeutic validation. Neither dismissing it wholesale nor accepting it uncritically is the right posture; research-framework caution, realistic expectations, and foundation-first lifestyle prioritization describes the defensible approach.

Quick Compare — Vilon vs Epithalon vs Thymalin vs Thymosin α1

Vilon is often grouped with the other Khavinson short peptides and the related thymic peptide family. Clear comparison:

• Vilon + Epithalon — The classical Khavinson longevity pair from the 2003 cohort study. The mortality signal is joint, not separable between the two.
• Vilon vs Thymalin — Vilon is the reductionist synthetic KE distilled from the Thymalin framework. Whether the dipeptide reproduces the polypeptide extract's activity is the central Khavinson reduction hypothesis.
• Vilon vs Thymosin α1 — Different molecules with fundamentally different evidence bases. Thymosin α1 has approved pharmaceutical status in >30 countries; Vilon is a research compound with Russian-cohort cohort signal only.

→ See Epithalon profile  •  → See Thymalin profile  •  → See Thymosin α1 profile

Supportive Nutrition & Adjuncts

Vilon's claimed immune-restoration signal is most plausible in the context of broader immune-axis optimization. Any genuine Vilon effect would plausibly be amplified by a well-supported baseline and masked by a depleted one.

• Zinc (15–25 mg elemental) with copper (1–2 mg) — Zinc is essential for thymic epithelial cell function and bioactive thymulin. Zinc deficiency attenuates immune response with or without Vilon.
• Vitamin D (target 40–60 ng/mL) — Foundational immune-axis input; deficiency is among the most common reversible immune-function problems in healthy adults.
• Selenium (100–200 µg) — Thyroid and immune-cell redox cofactor.
• Protein intake (≥1.2 g/kg) — Immune cells depend on amino-acid substrate availability; chronic under-eating is a reversible immune handicap.
• Sleep (7–9 hours) — The strongest behavioral lever on immune biology; sleep restriction impairs T-cell and NK-cell function measurably.
• Stress reduction — Chronic cortisol elevation suppresses thymic and peripheral immune function. Any claimed peptide effect on thymic biology competes with active cortisol-mediated suppression.
• Exercise (moderate, regular) — Improves immune surveillance and anti-inflammatory tone. Very intense / chronic overtraining has the opposite effect.
• Things to reduce — Chronic alcohol (thymic toxicity), chronic corticosteroid use without medical necessity, ultra-low-calorie dieting, chronic insufficient protein.

What to Expect — Timeline

Given the absence of controlled human data, this is a research-framework "what to expect" derived from Khavinson-group cohort descriptions and the short-peptide bioregulator framework. Treat as context rather than a usage guide.

• Day 1–7 — No expected subjective effect. Vilon does not produce acute receptor-level sensation.
• Week 1–3 (within course) — In Khavinson-framework reports, immune-parameter changes (lymphocyte subsets, NK activity) begin to emerge on laboratory testing. No reliable subjective marker.
• End of course (day 20) — Per Khavinson framework, gene-expression effects are established and persist after cessation.
• Inter-course interval (1–4 months) — Claimed to carry forward the transcriptional effects. Most Khavinson protocols cycle 2–3 times yearly.
• Long-term (multi-year cycled, per Khavinson & Morozov 2003) — The 2003 cohort associated multi-year cycled Vilon + Epithalon exposure with reduced all-cause mortality. This is the longest-horizon human data available.
• Non-responders — Common, not unusual. Younger, immune-competent subjects have less to gain than aged / immunosenescent hosts.
• If you feel worse — New autoimmune-spectrum symptoms (joint inflammation, rash, GI inflammation) warrant cessation and evaluation. Immunomodulators can unmask latent autoimmune predisposition.

Practical User Notes

• Confirm which Khavinson peptide you have — Vilon, Vesilute, Vesugen, Thymalin, Epithalon, and related peptides all share marketing and distribution channels. Label confusion is common.
• Start with nutritional foundations — Zinc, vitamin D, protein, sleep. A Vilon course layered on top of a depleted foundation is unlikely to produce measurable effect.
• Source discipline — Third-party HPLC + mass spec COA from an independent lab is the minimum standard. A dipeptide is among the easier peptides to synthesize but also among the easier to dilute or adulterate at commodity-vendor scale.
• Route choice — Oral / sublingual is the traditional Khavinson framework. SubQ injection is used in some research contexts with better pharmacokinetics but no superior efficacy documentation.
• Cycle discipline — Follow the 10–20 day on / multi-month off pattern. Continuous dosing is not the Khavinson protocol framework.
• Don't combine with active immunosuppression — Theoretical antagonism with cyclosporine, tacrolimus, biologics. Not appropriate for transplant or active autoimmune therapy patients without rheumatology / transplant-team oversight.
• Honest expectations — In the most optimistic framing, Vilon produces modest immune-parameter normalization in immunosenescent hosts. Dramatic transformation is not the claim.
• Better-evidenced alternatives exist — Documented immune deficiency → Thymosin α1 (Zadaxin) where approved. Aging-related immune decline → lifestyle (sleep, exercise, protein, zinc, vitamin D) produces broader benefit than any peptide.
• Track objectively — Baseline + post-course CBC with differential, hsCRP, zinc, vitamin D. Subjective immune-function reports are notoriously unreliable.
• Red flags to stop — New unexplained joint pain, rash, fever, GI inflammation, new autoimmune-spectrum symptom. Cessation first, evaluation second.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Vilon often also look at these:

Next Steps

Key References

1. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
2. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12373186.
3. Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel, 2005.
4. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19609712.
5. Khavinson VKh, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. PMID: 27905024.
6. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834146.
7. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2013;3(2):83-93.
8. Kuznik BI, Khavinson VKh, Linkova NS. Heat shock proteins, peptide bioregulators, and aging. Adv Gerontol. 2012;25(3):371-380.
9. Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. PMID: 24920421.
10. Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bull Exp Biol Med. 2016;161(1):175-178. PMID: 27265131.
11. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
12. World Anti-Doping Agency. 2025 WADA Prohibited List. WADA, 2025.